186.93 USD
-3.51 (-1.84%)
At close: Feb 9, 2026
186.93 USD
0 (0%)
After Hours: 2/9/2026, 8:12:35 PM
We assign a fundamental rating of 6 out of 10 to LGND. LGND was compared to 191 industry peers in the Pharmaceuticals industry. While LGND belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. LGND is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes LGND very considerable for growth investing!
1. Profitability
1.1 Basic Checks
- In the past year LGND was profitable.
- LGND had a positive operating cash flow in the past year.
- In multiple years LGND reported negative net income over the last 5 years.
- Each year in the past 5 years LGND had a positive operating cash flow.
1.2 Ratios
- LGND's Return On Assets of 3.29% is amongst the best of the industry. LGND outperforms 82.72% of its industry peers.
- LGND has a Return On Equity of 5.11%. This is amongst the best in the industry. LGND outperforms 83.25% of its industry peers.
- LGND's Return On Invested Capital of 1.58% is fine compared to the rest of the industry. LGND outperforms 78.53% of its industry peers.
- LGND had an Average Return On Invested Capital over the past 3 years of 1.12%. This is significantly below the industry average of 12.63%.
- The 3 year average ROIC (1.12%) for LGND is below the current ROIC(1.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROIC | 1.58% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
1.3 Margins
- LGND has a better Profit Margin (19.34%) than 90.58% of its industry peers.
- LGND has a better Operating Margin (11.48%) than 84.29% of its industry peers.
- In the last couple of years the Operating Margin of LGND has declined.
- LGND has a Gross Margin of 94.27%. This is amongst the best in the industry. LGND outperforms 96.34% of its industry peers.
- In the last couple of years the Gross Margin of LGND has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% |
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LGND is destroying value.
- LGND has more shares outstanding than it did 1 year ago.
- LGND has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for LGND is higher compared to a year ago.
2.2 Solvency
- LGND has an Altman-Z score of 5.64. This indicates that LGND is financially healthy and has little risk of bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 5.64, LGND is in the better half of the industry, outperforming 76.44% of the companies in the same industry.
- LGND has a debt to FCF ratio of 14.48. This is a negative value and a sign of low solvency as LGND would need 14.48 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 14.48, LGND is doing good in the industry, outperforming 77.49% of the companies in the same industry.
- A Debt/Equity ratio of 0.47 indicates that LGND is not too dependend on debt financing.
- LGND has a worse Debt to Equity ratio (0.47) than 61.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Altman-Z | 5.64 |
ROIC/WACC0.17
WACC9.46%
2.3 Liquidity
- LGND has a Current Ratio of 24.69. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- LGND's Current ratio of 24.69 is amongst the best of the industry. LGND outperforms 93.72% of its industry peers.
- LGND has a Quick Ratio of 24.30. This indicates that LGND is financially healthy and has no problem in meeting its short term obligations.
- LGND has a better Quick ratio (24.30) than 93.19% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 25.26% over the past year.
- Measured over the past years, LGND shows a quite strong growth in Earnings Per Share. The EPS has been growing by 13.44% on average per year.
- Looking at the last year, LGND shows a very strong growth in Revenue. The Revenue has grown by 64.83%.
- LGND shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.80% yearly.
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
3.2 Future
- Based on estimates for the next years, LGND will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.28% on average per year.
- The Revenue is expected to grow by 20.13% on average over the next years. This is a very strong growth
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- LGND is valuated quite expensively with a Price/Earnings ratio of 25.64.
- Based on the Price/Earnings ratio, LGND is valued a bit cheaper than the industry average as 79.06% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 28.06. LGND is around the same levels.
- LGND is valuated rather expensively with a Price/Forward Earnings ratio of 22.10.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of LGND indicates a somewhat cheap valuation: LGND is cheaper than 77.49% of the companies listed in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 27.86. LGND is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.64 | ||
| Fwd PE | 22.1 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, LGND is valued a bit cheaper than 78.01% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, LGND is valued a bit cheaper than the industry average as 74.87% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 119.6 | ||
| EV/EBITDA | 47.65 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- LGND has a very decent profitability rating, which may justify a higher PE ratio.
- LGND's earnings are expected to grow with 19.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.72
PEG (5Y)1.91
EPS Next 2Y21.72%
EPS Next 3Y19.77%
5. Dividend
5.1 Amount
- LGND does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
186.93
-3.51 (-1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-04 2026-03-04/amc
Inst Owners106.73%
Inst Owner Change-0.33%
Ins Owners1.62%
Ins Owner Change-1.3%
Market Cap3.68B
Revenue(TTM)251.23M
Net Income(TTM)48.58M
Analysts85.71
Price Target248.31 (32.84%)
Short Float %6.59%
Short Ratio5.68
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.83%
Min EPS beat(2)10.36%
Max EPS beat(2)57.31%
EPS beat(4)4
Avg EPS beat(4)19.98%
Min EPS beat(4)4.63%
Max EPS beat(4)57.31%
EPS beat(8)8
Avg EPS beat(8)37.45%
EPS beat(12)12
Avg EPS beat(12)53.58%
EPS beat(16)15
Avg EPS beat(16)61.91%
Revenue beat(2)2
Avg Revenue beat(2)25.66%
Min Revenue beat(2)6.44%
Max Revenue beat(2)44.89%
Revenue beat(4)4
Avg Revenue beat(4)18.43%
Min Revenue beat(4)6.44%
Max Revenue beat(4)44.89%
Revenue beat(8)8
Avg Revenue beat(8)17.31%
Revenue beat(12)11
Avg Revenue beat(12)12.65%
Revenue beat(16)14
Avg Revenue beat(16)16.25%
PT rev (1m)0%
PT rev (3m)32.94%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-10.34%
EPS NY rev (1m)3.65%
EPS NY rev (3m)10.42%
Revenue NQ rev (1m)0.65%
Revenue NQ rev (3m)-5.97%
Revenue NY rev (1m)-3.37%
Revenue NY rev (3m)12.73%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.64 | ||
| Fwd PE | 22.1 | ||
| P/S | 14.64 | ||
| P/FCF | 119.6 | ||
| P/OCF | 115.27 | ||
| P/B | 3.87 | ||
| P/tB | 9 | ||
| EV/EBITDA | 47.65 |
EPS(TTM)7.29
EY3.9%
EPS(NY)8.46
Fwd EY4.53%
FCF(TTM)1.56
FCFY0.84%
OCF(TTM)1.62
OCFY0.87%
SpS12.77
BVpS48.28
TBVpS20.77
PEG (NY)0.72
PEG (5Y)1.91
Graham Number88.99
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.29% | ||
| ROE | 5.11% | ||
| ROCE | 1.99% | ||
| ROIC | 1.58% | ||
| ROICexc | 2.92% | ||
| ROICexgc | 9.48% | ||
| OM | 11.48% | ||
| PM (TTM) | 19.34% | ||
| GM | 94.27% | ||
| FCFM | 12.24% |
ROA(3y)0.61%
ROA(5y)1.2%
ROE(3y)0.46%
ROE(5y)1.58%
ROIC(3y)1.12%
ROIC(5y)1.78%
ROICexc(3y)1.91%
ROICexc(5y)2.67%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)2.25%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.87%
ROICexc growth 5YN/A
OM growth 3Y-21.5%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.37%
GM growth 5Y0.62%
F-Score5
Asset Turnover0.17
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.47 | ||
| Debt/FCF | 14.48 | ||
| Debt/EBITDA | 7.07 | ||
| Cap/Depr | 3.38% | ||
| Cap/Sales | 0.46% | ||
| Interest Coverage | 96.15 | ||
| Cash Conversion | 50.63% | ||
| Profit Quality | 63.32% | ||
| Current Ratio | 24.69 | ||
| Quick Ratio | 24.3 | ||
| Altman-Z | 5.64 |
F-Score5
WACC9.46%
ROIC/WACC0.17
Cap/Depr(3y)71.95%
Cap/Depr(5y)50.12%
Cap/Sales(3y)19.71%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.26%
EPS 3Y-3.83%
EPS 5Y13.44%
EPS Q2Q%67.93%
EPS Next Y35.4%
EPS Next 2Y21.72%
EPS Next 3Y19.77%
EPS Next 5Y15.28%
Revenue 1Y (TTM)64.83%
Revenue growth 3Y-15.51%
Revenue growth 5Y6.8%
Sales Q2Q%67.71%
Revenue Next Year48.19%
Revenue Next 2Y27.54%
Revenue Next 3Y24.22%
Revenue Next 5Y20.13%
EBIT growth 1Y64.02%
EBIT growth 3Y-33.67%
EBIT growth 5YN/A
EBIT Next Year674.52%
EBIT Next 3Y155.59%
EBIT Next 5Y79.19%
FCF growth 1Y-61.26%
FCF growth 3Y10.8%
FCF growth 5YN/A
OCF growth 1Y-66.41%
OCF growth 3Y7.19%
OCF growth 5YN/A
LIGAND PHARMACEUTICALS / LGND FAQ
What is the ChartMill fundamental rating of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a fundamental rating of 6 / 10 to LGND.
What is the valuation status of LIGAND PHARMACEUTICALS (LGND) stock?
ChartMill assigns a valuation rating of 5 / 10 to LIGAND PHARMACEUTICALS (LGND). This can be considered as Fairly Valued.
How profitable is LIGAND PHARMACEUTICALS (LGND) stock?
LIGAND PHARMACEUTICALS (LGND) has a profitability rating of 7 / 10.
What is the financial health of LIGAND PHARMACEUTICALS (LGND) stock?
The financial health rating of LIGAND PHARMACEUTICALS (LGND) is 6 / 10.